Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AXSM save search
Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon
Published: 2023-07-26 (Crawled : 21:00) - prnewswire.com
COYA | $7.87 -6.75% -7.24% 54K
|
|
| O: 0.0%
H: 1.87%
C: 0.5%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.06%
H: 1.18%
C: 0.37%
SEEL | $0.3502 3.61% 3.48% 290K
|
Health Technology
|
| O: 1.48%
H: 0.73%
C: -2.19%
PRTA 4 | $21.17 2.92% 2.83% 510K
|
Health Technology
|
| O: 1.08%
H: 2.08%
C: 1.79%
PASG | $1.15 -4.17% -4.35% 280K
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -8.82%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.56%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 1.22%
H: 0.0%
C: -1.42%
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 0.6%
H: 1.74%
C: 1.24%
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: 0.43%
H: 0.85%
C: -2.12%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.56%
H: 3.6%
C: 0.99%
companies active dementia market
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dollar General Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DG
Published: 2023-12-25 (Crawled : 16:00) - prnewswire.com
BCS | News | $9.35 1.19% 0.0% 16M
|
Finance
| Email alert
Add to watchlist
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
| Email alert
Add to watchlist
BCLYF | News | $2.28 -10.14% 610
|
Finance
| Email alert
Add to watchlist
DG 4 | $144.82 -0.59% 0.0% 1.5M
|
Retail Trade
| Email alert
Add to watchlist
corporation deadline global
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCS, BCLYF
Published: 2023-11-27 (Crawled : 01:00) - prnewswire.com
BCLYF | News | $2.28 -10.14% 610
|
Finance
|
| O: 0.0%
H: 0.28%
C: -1.97%
BCS | News | $9.35 1.19% 0.0% 16M
|
Finance
|
| O: -0.69%
H: 0.42%
C: -0.42%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.1%
H: 5.89%
C: 5.83%
AHCO | $9.34 -0.21% -0.21% 1.1M
|
Finance
|
| O: 0.35%
H: 2.37%
C: 1.16%
deadline
Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-02 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.71%
H: 0.34%
C: -0.86%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
therapeutics results
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Published: 2022-05-09 (Crawled : 12:00) - prnewswire.com
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi acquisition narcolepsy therapeutics solriamfetol
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
Published: 2022-05-09 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi therapeutics solriamfetol
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
Published: 2022-03-28 (Crawled : 12:00) - biospace.com/
HTGC F | $18.46 1.15% 0.38% 660K
|
Finance
|
| O: -0.11%
H: 0.05%
C: -0.6%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.42%
H: 0.14%
C: -2.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.14%
H: 7.73%
C: -3.73%
sunosi therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
Published: 2022-03-28 (Crawled : 12:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.42%
H: 0.14%
C: -2.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.14%
H: 7.73%
C: -3.73%
sunosi therapeutics solriamfetol
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 11.35%
H: 9.32%
C: -4.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
cyb003 rapid positive depression meeting
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Published: 2021-11-08 (Crawled : 12:15) - globenewswire.com
HTGC F | $18.46 1.15% 0.38% 660K
|
Finance
|
| O: -0.11%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -1.44%
H: 12.29%
C: 8.6%
financial results results
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Published: 2023-02-22 (Crawled : 13:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.26%
H: 0.72%
C: -0.1%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.21%
H: 1.23%
C: -2.52%
sunosi europe commercialization license therapeutics agreement solriamfetol
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.01%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.43%
H: 0.72%
C: -2.96%
therapeutics
Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates DelveInsight | Leading Companies in the Market - Kyowa Kirin Acceleron, Cumberland, Horizon, CSL Behring, Seagen, Janssen
Published: 2023-10-05 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -1.5%
H: 5.49%
C: 3.39%
companies sclerosis growth market
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo
Published: 2023-10-04 (Crawled : 21:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.72%
H: 0.0%
C: 0.0%
RVMD S | $34.95 -2.46% -2.52% 1.2M
|
Health Technology
|
| O: -0.58%
H: 4.83%
C: 4.38%
IOVA | News M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: 0.24%
H: 3.66%
C: 1.95%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.44%
H: 1.52%
C: 0.08%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.43%
H: 4.97%
C: 4.71%
lung companies cancer study market
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN | $29.43 1.94% 1.9% 360K
|
Health Technology
|
| O: -0.11%
H: 0.82%
C: -2.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics growth study market
Attention-Deficit/Hyperactivity Disorder Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies in the Market - Cingulate, Otsuka, Supernus, Neurocentria, ABVC BioPharma, Axsome, BioLite, Mind Medicine
Published: 2023-09-11 (Crawled : 16:00) - prnewswire.com
SUPN | $29.43 1.94% 1.9% 360K
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: -3.5%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.4%
H: 0.26%
C: -0.46%
companies market
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
Published: 2023-10-11 (Crawled : 11:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: -0.16%
H: 0.93%
C: 0.85%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 4.47%
H: 2.11%
C: 1.52%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.11%
H: 1.04%
C: -0.41%
therapeutics
Narcolepsy Market Analysis, Market Size, Epidemiology, and Competitive Analysis of Leading Companies Including Takeda, Suven Life Sciences Limited, Axsome Therapeutics, Inc., Avadel, and Others by DelveInsight
Published: 2023-10-03 (Crawled : 21:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.66%
H: 2.5%
C: 1.89%
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.82%
H: 5.05%
C: 4.42%
companies life narcolepsy sciences market
AXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Published: 2023-11-26 (Crawled : 00:00) - prnewswire.com
SLRN | $5.0 2.46% 2.4% 2.4M
|
|
| O: 0.0%
H: 1.37%
C: -0.46%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.1%
H: 5.89%
C: 5.83%
AHCO | $9.34 -0.21% -0.21% 1.1M
|
Finance
|
| O: 0.35%
H: 2.37%
C: 1.16%
trusted deadline
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.34%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.13%
H: 1.36%
C: -1.45%
disease alzheimer’s global therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.